+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Role of CYP3A4 and P-glycoprotein in drug interactions involving the HMG-CoA reductase inhibitors



Role of CYP3A4 and P-glycoprotein in drug interactions involving the HMG-CoA reductase inhibitors



Journal of the American Pharmaceutical Association 41(1): 5-6




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 047281400

Download citation: RISBibTeXText

PMID: 11216112


Related references

Predicting drug-drug interactions involving the inhibition of intestinal CYP3A4 and P-glycoprotein. Current Drug Metabolism 11(9): 762-777, 2011

Predicting Drug Drug Interactions Involving the Inhibition of Intestinal Cyp3A4 and P-Glycoprotein. Current Drug Metabolism 11(9): 762-777, 2010

Drug-drug interactions involving CYP3A4 and p-glycoprotein in hospitalized elderly patients. European Journal of Internal Medicine 2019, 2019

PXR/CYP3A4-humanized mice for studying drug-drug interactions involving intestinal P-glycoprotein. Molecular Pharmaceutics 10(3): 1056-1062, 2013

Method for predicting the risk of drug-drug interactions involving inhibition of intestinal CYP3A4 and P-glycoprotein. Xenobiotica; the Fate of Foreign Compounds in Biological Systems 39(6): 430-443, 2009

The consequence of regional gradients of P-gp and CYP3A4 for drug-drug interactions by P-gp inhibitors and the P-gp/CYP3A4 interplay in the human intestine ex vivo. Toxicology in Vitro 40: 26-33, 2016

Prediction of in vivo drug-drug interactions from in vitro data : factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4. Clinical Pharmacokinetics 45(10): 1035-1050, 2006

Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of losartan and its main metabolite EXP-3174 in rats: possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase inhibitors. Pharmacology 88(1-2): 1-9, 2012

Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of nifedipine in rats: Possible role of P-gp and CYP3A4 inhibition by HMG-CoA reductase inhibitors. Pharmacological Reports 67(1): 44-51, 2016

Utility of CYP3A4 and PXR-CAR-CYP3A4/3A7 Transgenic Mouse Models To Assess the Magnitude of CYP3A4 Mediated Drug-Drug Interactions. Molecular Pharmaceutics 14(5): 1754-1759, 2017

Investigating the binding interactions of the anti-Alzheimer's drug donepezil with CYP3A4 and P-glycoprotein. Bioorganic and Medicinal Chemistry Letters 25(2): 297-301, 2015

A physiologically based pharmacokinetic modeling approach to predict drug-drug interactions between domperidone and inhibitors of CYP3A4. Biopharmaceutics and Drug Disposition 37(1): 15-27, 2016

In Vitro Screening of Six Protein Kinase Inhibitors for Time-Dependent Inhibition of CYP2C8 and CYP3A4: Possible Implications with regard to Drug-Drug Interactions. Basic and Clinical Pharmacology and Toxicology 123(6): 739-748, 2018

Pharmacokinetic drug-drug interaction between ethinyl estradiol and gestodene, administered as a transdermal fertility control patch, and two CYP3A4 inhibitors and a CYP3A4 substrate. European Journal of Drug Metabolism and Pharmacokinetics 40(4): 389-399, 2016

Use of a Physiologically Based Pharmacokinetic Model for Quantitative Prediction of Drug-Drug Interactions via CYP3A4 and Estimation of the Intestinal Availability of CYP3A4 Substrates. Journal of Pharmaceutical Sciences 104(9): 3183-3193, 2016